Have we reached ‘peak HEOR’?
That is the title of my guest column at The Evidence Base. An excerpt is…
Have we reached ‘peak HEOR’?
That is the title of my guest column at The Evidence Base. An excerpt is below: Multiple indicators suggest that health economics and outcomes research (HEOR) faces unprecedented challenges to its traditional role in pharmaceutical value demonstration. Yet these apparent threats may signal evolution rather than decline – if the field can adapt to serve…
What Full-Circle EMS–Hospital Interoperability Looks Like in Practice
From field documentation to post-discharge outcomes, interoperability isn’t a future ideal — it’s a present necessity. Here’s what seamless EMS–hospital data exchange looks like, and why it matters now. The post What Full-Circle EMS–Hospital Interoperability Looks Like in Practice appeared first on MedCity News.
Enhanced Direct Enrollment: Georgia Access and the Power of Partnership
[Sponsored] Across the nation, state-based health insurance exchanges are searching for ways to better serve their communities while making enrollment easier, more personal, and more accessible for everyone. The post Enhanced Direct Enrollment: Georgia Access and the Power of Partnership appeared first on MedCity News.
AI-Based Simulation Training is Key to Solving Dentistry’s Procedural Skills Crisis
Giving dentists more hands-on training provides a platform for repeated practice, real-time feedback, and continuous improvement, helping prepare students with the confidence and consistency they need to succeed in patient care. The post AI-Based Simulation Training is Key to Solving Dentistry’s Procedural Skills Crisis appeared first on MedCity News.
BMS Joins the In Vivo Cell Therapy Chase With $1.5B Orbital Therapeutics Acquisition
Startup Orbital Therapeutics brings Bristol Myers Squibb an in vivo cell therapy in development for treating autoimmune disease. With the deal, BMS joins AstraZeneca, AbbVie, and Gilead Sciences in turning to M&A as a way to get in vivo cell therapy assets and technologies. The post BMS Joins the In Vivo Cell Therapy Chase With…
Redesigning Healthcare: How Accessible Data Leads to Better Care
Value-based care promises to right the wrongs of fee-based healthcare. But today, we’re a long way from a value-based system. One way to get there faster? Prioritize access to data. The post Redesigning Healthcare: How Accessible Data Leads to Better Care appeared first on MedCity News.
Creating Stability Through Change: Embedding Succession Planning in Healthcare Culture
Without structured succession strategies, organizations risk instability, operational disruptions, and over-reliance on interim leadership. Here are some strategies to safeguard the future of hospitals and health systems. The post Creating Stability Through Change: Embedding Succession Planning in Healthcare Culture appeared first on MedCity News.
Parents Can and Should Be Active Participants in Autism Therapy
One in every 31 children is diagnosed with some form of autism today, up from previous years — and regardless of why we have more cases, the more pressing question is how we should address the dramatic increase in support needs. The post Parents Can and Should Be Active Participants in Autism Therapy appeared first…
Journalists Dig Into Government Shutdown and Rural Doctor Drought
KFF Health News chief Washington correspondent Julie Rovner appeared on CNN’s “Quest Means Business” to discuss the Affordable Care Act subsidies at the core of the government shutdown on Oct. 2. Rovner also appeared on NPR’s “Morning Edition” to discuss the subsidies on Oct. 7. Click here to watch Rovner on “Quest Means Business.” Click…
Chiesi’s Rare Disease Strategy Expands to Genetic Meds via Alliance With CRISPR Startup Arbor
Chiesi Global Rare Diseases is committing up to $115 million to begin a collaboration on Arbor Biotechnologies’ in vivo gene-editing therapy for primary hyperoxaluria type 1, an inherited liver disorder. It’s the rare disease company’s first foray into genetic medicines. The post Chiesi’s Rare Disease Strategy Expands to Genetic Meds via Alliance With CRISPR Startup…
